相关实验视频

Updated: Jul 16, 2025

In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma
12:48

In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma

Published on: May 11, 2015

10.6K

眼生物标志物和阿尔茨海默氏病

Snježana Kaštelan1, Marijana Braš2, Neda Pjevač3

  • 1Department of Ophthalmology, Clinical Hospital Dubrava, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.

International journal of molecular sciences
|September 9, 2023
PubMed
概括

研究人员正在探索眼作为阿尔茨海默病 (AD) 生物标志物的潜在来源. 在眼中识别这些生物标志物可能会导致早期检测和监测AD的非侵入性诊断方法.

关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.生物标志物 生物标志物痴呆症 痴呆症是一种痴呆症.早期诊断的早期诊断是什么神经认知障碍是一种神经认知障碍.预后 预后 预后眼 眼 眼 眼

更多相关视频

Author Spotlight: Advancing Tear Fluid Analysis Using a Standardized Protocol for Proteomics Research08:20

Author Spotlight: Advancing Tear Fluid Analysis Using a Standardized Protocol for Proteomics Research

Published on: December 1, 2023

2.4K
Author Spotlight: Isolating Biomolecules from Mouse Tears — A Methodology for Molecular Analysis and Biomarker Research09:04

Author Spotlight: Isolating Biomolecules from Mouse Tears — A Methodology for Molecular Analysis and Biomarker Research

Published on: July 19, 2024

1.5K

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212